

KLF6 Antibody (C-term)

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP6588B

Product Information

Application	WB, IHC-P, FC, IF, E
Primary Accession	Q99612
Reactivity	Human, Rat, Mouse
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	31865
Antigen Region	159-186

Additional Information

Gene ID	1316
Other Names	Krueppel-like factor 6, B-cell-derived protein 1, Core promoter element-binding protein, GC-rich sites-binding factor GBF, Proto-oncogene BCD1, Suppressor of tumorigenicity 12 protein, Transcription factor Zf9, KLF6, BCD1, COPEB, CPBP, ST12
Target/Specificity	This KLF6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 159-186 amino acids from the C-terminal region of human KLF6.
Dilution	WB~~1:1000 IHC-P~~1:100~500 FC~~1:10~50 IF~~1:10~50 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.05% (V/V) Proclin 300. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	KLF6 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	KLF6
Synonyms	BCD1, COPEB, CPBP, ST12

Function	Transcriptional activator (By similarity). Binds a GC box motif. Could play a role in B-cell growth and development.
Cellular Location	Nucleus.
Tissue Location	Highly expressed in placenta followed by spleen, thymus, prostate, testis, small intestine and colon. Weakly expressed in pancreas, lung, liver, heart and skeletal muscle. Also expressed in fetal brain, spleen and thymus


Background

COPEB is a member of the Kruppel-like family of transcription factors. The zinc finger protein is a transcriptional activator, and functions as a tumor suppressor.


References

Sangodkar,J., Eur. J. Cancer 45 (4), 666-676 (2009) DiFeo,A., Drug Resist. Updat. 12 (1-2), 1-7 (2009)

Images





All lanes : Anti-KLF6 Antibody (C-term) at 1:1000 dilution
Lane 1: HT-29 whole cell lysate Lane 2: mouse stomach tissue lysate Lysates/proteins at 20 µg per lane.
Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ASP1615) at 1/15000 dilution. Observed band size : 35kDa Blocking/Dilution buffer: 5% NFDM/TBST.




Western blot analysis of KLF6 Antibody (C-term) (Cat. #AP6588b) in mouse stomach tissue lysates (35ug/lane). KLF6 (arrow) was detected using the purified Pab.

Formalin-fixed and paraffin-embedded human testis tissue reacted with KLF6 Antibody (C-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.



Flow cytometric analysis of wdr cells using KLF6 Antibody (C-term)(bottom histogram) compared to a negative control cell (top histogram) FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.



Fluorescent confocal image of HeLa cell stained with KLF6 Antibody (C-term)(Cat#AP6588b). HeLa cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.1%, 10 min), then incubated with KLF6 primary antibody (1:25, 1 h at 37°C). For secondary antibody, Alexa Fluor® 488 conjugated donkey anti-rabbit antibody (green) was used (1:400, 50 min at 37°C). Cytoplasmic actin was counterstained with Alexa Fluor® 555 (red) conjugated Phalloidin (7 units/ml, 1 h at 37°C). Nuclei were counterstained with DAPI (blue) (10 µg/ml, 10 min). KLF6 immunoreactivity is localized to Nucleus significantly.

Citations

- [Krüppel-like Factor 6 Suppresses the Progression of Pancreatic Cancer by Upregulating Activating Transcription Factor 3](#)
- [MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis.](#)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.